Elise C. Kohn

Nov 4, 2024 | ascopubs.org | Hillary Andrews |Lisa M. McShane |Elise C. Kohn

1-3 Patients with high-grade serous ovarian cancer (HGSOC) whose tumors are HRD have better outcomes when treated with PARPi maintenance therapy.4-7 Nearly half of patients with HGSOC have HRD, and approximately half of patients with HRD or about 20% of all patients with HGSOC have a deleterious or potentially deleterious mutation in BRCA1 or BRCA2 (BRCA1/2),7-10 which are integral to the homologous recombination repair (HRR) pathway.

Dec 16, 2023 | acsjournals.onlinelibrary.wiley.com | Melissa Lumish |Elise C. Kohn |William P. Tew

CONFLICT OF INTEREST STATEMENT The authors declared no conflicts of interest. REFERENCES 1, , , et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020; 38(11): 1222-1245. 2, , , et al. LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): phase IIIb OReO/ENGOT Ov-38 trial [abstract]. Ann Oncol. 2021; 32(suppl 5): S1308-S1309.